Multistakeholder perspectives on Joint Clinical Assessment in Europe: what are the opportunities and challenges for improving patient access to new treatments?

19 Jun 2023

Written by Casper Paardekooper (Vintura), Herbert Altmann (PharmaLex), Tommy Bramley (AmerisourceBergen)

Decision science Health technology assessment Interviews Market access

Images of Tommy Bramley, Herbert Altmann and Casper Paardekooper discussing joint clinical assessment

The Regulation (EU) 2021/2282EN on health technology assessment (HTAR) came into effect in January 2022 and, when fully applied from January 2025, is set to transform HTA in Europe. To be implemented under this regulation, the Joint Clinical Assessment (JCA) process aims to streamline the assessment process of new medical treatments and devices across Europe with the ultimate goal of improving patient access to novel therapies. In this interview, we speak with Tommy Bramley, PhD, SVP of Global Consulting at AmerisourceBergen, Herbert Altmann, PhD, Head of Commercialization and Access Solutions Europe at PharmaLex and Casper Paardekooper, partner at the strategic...